Empowering Early Detection

With Novel Diagnostics

A series of brain scans showing the progression of a neurodegenerative disease over time.

Our focus at APN LifeSciences: making early detection and diagnosis of degenerative brain disease possible.

Neurodegenerative diseases are relentless, often fatal diseases that affect every part of a patient's life.

Early detection of disease is associated with significantly improved outcomes and quality of life for patients. But advancements in the early detection of neurodegenerative diseases has stagnated.

That's where we come in. APN LifeSciences' pipeline of novel tracers and PET imaging system technology aims to accurately visualize brain abnormalities in patients, enabling clinicians to accurately differentiate disease types at the earliest possible stage, providing patients with the best treatment possible.

Our Science

Our Tracer

Our Tech

Our System

Tau protein accumulation is the current gold standard for dementia diagnosis. APN LifeSciences' Tau PET imaging agent, APN-1607 (Florzolotau 18F), exhibits high specificity for Tau protein and can identify various types of dementia, including Alzheimer's Disease, progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD).

Using a traditional or helmet-type PET scanner combined with AI-powered image processing and recognition, our imaging agent enables clear visualization of brain pathology. It supports clinicians in making accurate differential diagnoses, facilitates early detection and disease staging, and helps predict treatment outcomes.

APN LifeSciences is actively developing a brain health management system. Our goal is to create an accessible and convenient diagnostic environment for all patients. Our health management system will be able to enable effective monitoring of a wide variety of neurodegenerative diseases, ensuring timely diagnosis and personalized treatment.

The Problem

Neurodegenerative diseases are relentless, often fatal diseases that affect every part of a patient's life.

Early detection of diseases like Alzheimer's Disease and Parkinson's disease is associated with significantly improved outcomes and quality of life for patients. But advancements in early detection of neurodegenerative diseases have stagnated.

Our Pipeline

18F-APN-1607
Tau PET Tracer
(florzolotau)

Indication:

Alzheimer's Disease

Region:

China

Development Status:

Phase III

Collaborators:

Dongcheng Pharma

[18F]-APN-1607 (florzolotau (18F)) is a new generation tau PET imaging tracer with a largely improved off-target profile.

florzolotau (18F) recognizes pathological tau aggregates in all tauopathies such as AD, PSP, CBD, PSP, and PiD, providing a unified PET imaging solution for those diseases. With a single PET scan, florzolotau (18F) provides a high-resolution, quantifiable 3-D map revealing the brain distribution of toxic tau protein in all kinds of tauopathies, conveying key information for clinicians to conduct differential diagnosis.